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ABSTRACT
Objective: National guidelines recommend ‘early’
coronary angiography within 96 h of presentation for
patients with non-ST elevation acute coronary
syndromes (NSTE-ACS). Most patients with NSTE-ACS
present to their district general hospital (DGH), and
await transfer to the regional cardiac centre for
angiography. This care model has inherent time delays,
and delivery of timely angiography is problematic. The
objective of this study was to assess a novel clinical
care pathway for the management of NSTE-ACS,
known locally as the Heart Attack Centre-Extension or
HAC-X, designed to rapidly identify patients with NSTE-
ACS while in DGH emergency departments (ED) and
facilitate transfer to the regional interventional centre
for ‘early’ coronary angiography.
Methods: This was an observational study of 702
patients divided into two groups; 391 patients treated
before the instigation of the HAC-X pathway (Pre-
HAC-X), and 311 patients treated via the novel pathway
(Post-HAC-X). Our primary study end point was time
from ED admission to coronary angiography. We also
assessed the length of hospital stay.
Results: Median time from ED admission to coronary
angiography was 7.2 (IQR 5.1–10.2) days pre-HAC-X
compared to 1.0 (IQR 0.7–2.0) day post-HAC-X
(p<0.001). Median length of hospital stay was 3.0
(IQR 2.0–6.0) days post-HAC-X v 9.0 (IQR 6.0–14.0)
days pre-HAC-X (p<0.0005). This equates to a
reduction of six hospital bed days per NSTE-ACS
admission.
Conclusions: The introduction of this novel care
pathway was associated with significant reductions in
time to angiography and in total hospital bed
occupancy for patients with NSTE-ACS.
INTRODUCTION
Acute coronary syndromes (ACS) encompass a
spectrum of clinical presentations that include
ST elevation myocardial infarction (STEMI),
non-STEMI (NSTEMI), and unstable angina.
In recent years, patients who present with
STEMI have beneﬁted from a shift from
thrombolytic therapy to primary percutaneous
coronary intervention (PCI).1 2 The latest
Myocardial Ischaemia National Audit Project
(MINAP) data demonstrates that this change
in practice has been implemented remarkably
quickly across most parts of the UK so that the
majority of patients with STEMI are now
treated with primary PCI.3 Targets supported
by the Health Care Commission based on time
from symptom onset to opening of the
infarct-related artery set a standard against
which models of care for patients with STEMI
are measured and these targets have driven
reductions in treatment times and improved
clinical outcomes.3
Strengths and limitations of this study
▪ Delivery of early coronary angiography for
patients with non-ST elevation acute coronary
syndromes (NSTE-ACS) remains a problem
within the UK.
▪ We describe the introduction of a clinical
pathway aimed to facilitate early coronary angi-
ography and reduced length of hospital admis-
sion for patients with NSTE-ACS.
▪ Our ‘real world’ data demonstrates that this
streamlined care pathway can dramatically cut
inpatient waiting times for coronary angiography
with a resultant reduction in length of hospital
admission.
▪ Importantly this is not randomised data. The
study describes our management of patients
with NSTE-ACS before and after the introduction
of this clinical pathway. As with all observational
studies it is open to residual bias and potential
confounding.
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Non-ST elevation ACS (NSTE-ACS) accounts for a far
greater proportion of ACS admissions than STEMI each
year.3 NSTE-ACS is considered a ‘high-risk’ clinical condi-
tion, associated with 1 year mortality rates greater than or
equal to those seen after STEMI.4 International treatment
guidelines recommend that patients with NSTE-ACS are
managed with immediate medical therapy followed by
early coronary angiography (and PCI if appropriate)
within 72–96 h of hospital admission,5 and within 24 h for
the highest risk patients.5 Despite these guidelines recom-
mending early invasive management of patients with
NSTE-ACS, standard care pathways rarely achieve these
evidence-based treatment timeframes.
The delivery of care for patients with NSTE-ACS has
changed little in the past 10 years. Most patients with
NSTE-ACS present to a hospital without a cardiac cath-
eter laboratory where they wait for transfer to the
regional interventional cardiac centre for coronary angi-
ography.6 This model of care results in unacceptable
delays to treatment7 which are detrimental to patient
outcomes and which waste healthcare resources. A sys-
tematic approach to early diagnosis, risk stratiﬁcation
and ‘direct’ transfer to an interventional cardiac centre
has the potential to minimise unnecessary delays for cor-
onary angiography, to reduce hospital stays and to
prevent recurrent ischaemic cardiac events in higher
risk patients.
The London Chest Hospital is a regional interven-
tional cardiac centre serving a population of approxi-
mately 1.8 million in North East London. The hospital
provides coronary angiography, PCI and cardiac surgery
for six district general hospitals (DGH) in the region.
We have devised a new clinical pathway for the manage-
ment of patients with NTE-ACS that built on our experi-
ence from developing a network-wide STEMI service.
This new pathway known locally as the Heart Attack
Centre Extension or ‘HAC-X’ service aims to transfer
those patients with NSTE-ACS who can be diagnosed
within 4 h of presentation directly from the ED to the
regional interventional cardiac centre avoiding unneces-
sary admission to the local hospital.
This article represents a prospective study that moni-
tored the implementation of this novel clinical HAC-X
pathway for the management of patients with
NSTE-ACS. The aim of the HAC-X pathway was to facili-
tate the early invasive management of patients with
NSTE-ACS. Potentially this streamlined approach to
NSTE-ACS management would represent a more efﬁ-
cient use of NHS resources.
METHODS
We have undertaken a prospective observational study of
the management of patients with NSTE-ACS treated at
our institution between October 2009 and October
2010. This study period represents the last 6 months of
our previous NSTE-ACS care model and the ﬁrst
6 months of the new HAC-X pathway.
Study population
Patients were eligible for inclusion in this study if they
presented to a DGH ED participating in the HAC-X
project and were subsequently transferred to our institu-
tion for further management.
Inclusion criteria for the HAC-X clinical pathway
(box 1) and therefore study inclusion criteria were an
admission diagnosis of NSTE-ACS with chest pain within
24 h of presentation plus either an elevated blood tropo-
nin T or troponin I concentration, or ECG changes com-
patible with ischaemia (deﬁned as ST-segment
depression ≥1 mm or T-wave inversion ≥2 mm in two
contiguous leads, or biphasic ST/T wave segments indi-
cative of a critical stenosis in the left anterior descending
artery). Patients were excluded if they had a contraindi-
cation to early interventional management including
major medical comorbidity, unexplained anaemia
(haemoglobin concentration <10 g/dL), acute renal
failure, recent traumatic injury or loss of consciousness
(except when secondary to cardiac arrhythmia), overt
sepsis or unexplained hypoxia.
During the 12-month study period, 702 patients with
NSTE-ACS were treated at our institution. These patients
were divided into two groups for subsequent analysis;
391 patients treated before the instigation of the HAC-X
pathway (pre-HAC-X), and 311 patients treated via the
novel pathway (post-HAC-X).
Study protocol
The London Chest Hospital is a ‘stand-alone’ regional
interventional cardiac centre. It has no onsite emer-
gency department (ED) and only patients with sus-
pected STEMI are admitted directly to the hospital. All
patients with suspected NSTE-ACS must ﬁrst be seen at a
DGH before transfer.
During the ﬁrst 6 months of the study period
(pre-HAC-X) the model of care for patients with
NSTE-ACS involved admission to their local DGH for
‘medical stabilisation’ pending availability of a bed at the
regional interventional cardiac centre for transfer for
Box 1 Inclusion and Exclusion Criteria for HAC-X clinical pathway
Inclusion criteria
Symptoms suggestive of myocardial ischaemia
With a positive troponin assay
OR ECG changes including:
ST depression;
T wave inversion in V1-4;
Dynamic T wave changes
Exclusion criteria
Unexplained anaemia (haemoglobin <10 g/dL)
Hypoxia
Acute renal failure
Loss of consciousness (unless secondary to cardiac arrhythmia)
Recent trauma
Overt sepsis
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coronary angiography (and/or PCI). Clinical instability
prompted more urgent transfer and patients were
usually transferred back to their local hospital for dis-
charge following invasive cardiac treatment.
After the initiation of the HAC-X pathway in April
2010 (post HAC-X) patients diagnosed with NSTE-ACS
in the DGH ED, and meeting the inclusion criteria for
the HAC-X pathway (box 1) received protocol driven
evidence-based medical therapy (box 2) and were trans-
ferred to our institution directly within 1 h of diagnosis.
There was no requirement for ECG review or prior noti-
ﬁcation of the patient’s transfer to our centre but clin-
ical advice could be sought in cases of diagnostic
uncertainty. If the admission diagnosis of NSTE-ACS was
conﬁrmed at our centre, coronary angiography was per-
formed; unstable patients were taken directly for coron-
ary angiography. Stable patients had coronary
angiography scheduled for later the same day, or if the
patient arrived outside of standard working hours, cor-
onary angiography took place on the next available
routine list. All subsequent cardiac care was undertaken
at the regional cardiac centre. We aimed to discharge
patients within 48 h of their admission. Patients requir-
ing surgical revascularisation remained at our centre
until surgery was performed.
Outcome measures
Our primary study end point was time to coronary angi-
ography for patients with NSTE-ACS (deﬁned as the
time of registration at the DGH ED to beginning of the
angiogram procedure). We also measured length of hos-
pital stay (deﬁned as the time from registration at the
DGH ED to ﬁnal hospital discharge). In addition, we
have assessed the need for angiography and/or coronary
revascularisation, along with discharge diagnosis of the
post-HAC-X group.
Statistical analysis
Continuous data with a normal distribution are reported
as mean±SD. Skewed data are reported as median and
IQR. Categorical data are expressed as percentages.
Continuous variables with a normal distribution were
compared by Student’s t test. Skewed data were com-
pared using the Mann-Whitney U test. Categorical vari-
ables were compared by the χ2 or Fisher exact test.
Statistical signiﬁcance was deﬁned as p<0.05. Statistical
analyses were performed using SPSS V.18.0 (SPSS Inc,
Chicago, Illinois, USA).
RESULTS
Patient characteristics
In total 702 patients with NSTE-ACS were treated at our
institution during the study period (table 1). Three
hundred and ninety-one (55.7%) patients were treated
in the 6 months pre-HAC-X, and 311 (44.3%) patients
were treated in the 6 months post-HAC-X.
Patients in the post-HAC-X group were younger (57.0 vs
65.2 years; p<0.001) and were more likely to be or have
been smokers (58.8% vs 48.6%; p=0.009).
Hypercholesterolaemia (51.3% vs 46.0%; p<0.001), per-
ipheral vascular disease (6.0% vs 1.5%; p=0.003) and previ-
ous PCI (25.6 vs 14.1%; p<0.001) were also observed more
frequently in the post-HAC-X group.
Outcome of invasive investigation
Pre-HAC-X patients had the diagnosis of NSTE-ACS con-
ﬁrmed by a local cardiologist prior to transfer.
Therefore all of these patients underwent coronary
angiography (ﬁgure 1). Of these, 212 (54.2%) patients
subsequently underwent coronary revascularisation;
144/212 (67.9%) patients underwent PCI and 68/212
(32.1%) patients were referred for coronary artery
bypass graft (CABG) surgery. 179 of 391 (45.8%)
patients did not receive either PCI or CABG, but had
coronary disease requiring ongoing medical therapy.
Post-HAC-X 250 of the 311 (80.4%) patients trans-
ferred to our centre by the new pathway underwent cor-
onary angiography. Of these, 144/250 (57.6%)
subsequently underwent coronary revascularisation;
108/144 (75.0%) patients underwent PCI and 36/144
(25.0%) patients were referred for CABG surgery, and
106/250 (42.4%) patients were treated with medical
therapy alone.
Time to coronary angiography
The initiation of the HAC-X pathway led to signiﬁcant
reductions in the median waiting time from DGH ED
admission to coronary angiography for patients with
NSTE-ACS. Pre-HAC-X time to angiography was 7.2
(IQR 5.1–10.2) days; post-HAC-X this had reduced to 1.0
(IQR 0.7–2.0) days (p<0.001; ﬁgure 2). Pre-HAC-X only
18% of patients with NSTE-ACS underwent coronary
angiography within the recommended 96 h from pres-
entation. Post-HAC-X 90% of patients underwent coron-
ary angiography within this timeframe (ﬁgure 3).
Length of hospital stay
Median length of hospital stay reduced signiﬁcantly
from 9.0 (IQR 6.0–14.0) days pre-HAC-X to 3.0 (IQR
2.0–6.0) days post-HAC-X (p<0.001). This equates to a
saving of six hospital bed days per NSTE-ACS admission.
As 311 patients with NSTE-ACS were treated according
the HAC-X pathway during its ﬁrst 6 months of oper-
ation we estimated that 1866 hospital bed days were
saved during this period.
Box 2 Evidence based immediate medical therapy for
patients with NSTEMI treated via the HAC-X clinical pathway
Immediate evidence based therapy given at DGH included
Aspirin 300 mg
Clopidogrel 600 mg
Fondaparinux 2.5 mg
Eptifibatide bolus (180 mg/kg) as long as no contraindications
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Clinical efficacy of HAC-X pathway
In total 85.5% of patients admitted directly via the
HAC-X pathway had a cardiological diagnosis.
NSTE-ACS was the discharge diagnosis for 235 (75.5%)
of the 311 patients treated according to the HAC-X
pathway. A further 31/311 (10%) patients had another
cardiac cause for chest pain (including pericarditis or
myocarditis) whereas 45/311 (14.5%) of patients had a
non-cardiac cause for their symptoms.
DISCUSSION
The introduction of the HAC-X pathway led to a signiﬁ-
cant decrease in time from hospital admission to coron-
ary angiography for patients with NSTE-ACS.
Furthermore, the proportion of patients with NSTE-ACS
treated within the 96 h guideline target increased dramat-
ically from 18% pre-HAC-X to 90% post-HAC-X. This
novel clinical pathway facilitated the rapid, efﬁcient man-
agement of patients with NSTE-ACS, which has translated
into a two-thirds reduction in length of hospital stay.
Direct transfer of patients from the DGH to the
regional cardiac centre has proved a far more stream-
lined approach to NSTE-ACS care. Not only was the
length of hospital stay decreased, but all patients
managed via the HAC-X pathway also avoided an
unnecessary admission to their local DGH. The HAC-X
pathway was only feasible because all parties involved
(cardiac centre, DGHs and local healthcare commis-
sion) were motivated to contribute to the project. The
beneﬁt of the HAC-X pathway to the referring DGH is
immediately evident. Direct transfer of patients with
NSTE-ACS results in a huge reduction in ‘wasted’ hos-
pital bed days. Furthermore, the HAC-X pathway has an
additional cost beneﬁt as it avoids local healthcare com-
missioners from having to fund two admission tariffs for
Table 1 Clinical Characteristics of the study cohort
Variables
Pre-HAC-X
n=391
Post-HAC-X
n=311 p Value
Age (years) 65.2±12.6 57.0±13.9 <0.001
Gender 0.884
Male (%) 70.8 70.0
Female (%) 29.2 30.0
Smoking status: 0.009
Current (%) 18.2 29.6
Ex-smoker (%) 30.4 31.9
Never (%) 51.4 41.2
Diabetes: 0.205
Insulin requiring (%) 6.1 9.7
Non-Insulin requiring (%) 24.8 22.6
Not diabetic (%) 69.1 67.7
Hypertension (%) 62.7 59.7 0.241
Hypercholesterolaemia (%) 46.0 51.3 0.001
Previous myocardial infarction (%) 30.7 34.9 0.29
Previous PCI (%) 14.1 25.5 <0.001
Previous CABG (%) 11.5 11.2 0.994
Peripheral vascular disease (%) 1.5 6.0 0.003
Previous stroke (%) 6.7 8.1 0.58
CABG, coronary artery bypass graft; HAC-X, Heart Attack Centre-Extension.
Figure 1 Flow diagram of
patients with suspected acute
coronary syndromes treated
before (Pre-HAC-X, Heart Attack
Centre-Extension) and after
(Post-HAC-X) the initiation of the
HAC-X clinical pathway
describing access to coronary
angiography and subsequent
management strategy. CABG,
coronary artery bypass graft; PCI,
percutaneous coronary
intervention.
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the same index event. Prior to the initiation of the
HAC-X the local healthcare commission was paying
admission tariffs to the DGH and the regional cardiac
centre. Alternative transfer strategies for patients with
NSTE-ACS, such as regional transfer units,8 and same
day ‘repatriation’ of patients to the referring hospital
after PCI,9 have been described, and result in more efﬁ-
cient bed usage and reduced time to angiography in
patients with NSTE-ACS. However, these management
strategies require admission tariffs at the referring DGH
and also the cardiac centre. The HAC-X service did
require the cardiac centre to invest in more bed capacity
that inevitably increased the cost of the pathway to the
cardiac centre.
The success of this pathway, which aims to transfer
patients to a specialist centre without admission to the
local hospital is critically dependent on an accurate
early diagnosis both for obvious clinical reasons and, in
the UK, to facilitate transfer out of the ED within the
4 h target. Patients with NSTE-ACS form a heterogenous
group yet the simple inclusion criteria for the HAC-X
pathway of clinical symptoms of ACS plus either a posi-
tive point of care troponin assay or ECG changes consist-
ent with myocardial ischaemia enabled an accurate
diagnosis to be achieved in more than three-quarters of
patients. This is comparable with diagnostic accuracy
rates for patients delivered to Heart Attack Centres for
acute STEMI management.
The proportion of patients undergoing coronary
revascularisation post-HAC-X is in line with contempor-
ary observational data of NSTE-ACS management.10 It is
also similar to our historical revascularisation rates for
patients with NSTE-ACS. Therefore, diagnostic criteria
for the HAC-X pathway appear to perform as well the
traditional model of care in their ability to identify
patients with NSTE-ACS who will beneﬁt from revascu-
larisation. Importantly these diagnostic criteria identify
these patients more quickly. This is key to the success of
a model that aims to transfer patients direct from the
ED to the cardiac centre in a systematic way.
The inclusion criteria for the pre-HAC-X and
post-HAC-X cohorts are subtly different. Pre-HAC-X,
patients with suspected NSTE-ACS were admitted to the
DGH for medical stabilisation and cardiology review. If a
local cardiologist conﬁrmed the diagnosis of NSTE-ACS,
and felt coronary angiography was appropriate, then the
patients were transferred to the interventional cardiac
centre for invasive investigation and management. Thus
the pre-HAC-X cohort consisted only of patients with
conﬁrmed NSTE-ACS undergoing coronary angiog-
raphy. The post-HAC-X cohort consisted of patients with
suspected NSTE-ACS transferred directly from the ED.
The diagnosis of NSTE-ACS was not conﬁrmed until car-
diology review at the cardiac centre, and inevitably the
post-HAC-X cohort contained some patients who proved
to have an alternate diagnosis and did not undergo cor-
onary angiography.
Patients with a ﬁnal non-cardiac diagnosis comprised
about 15% of post-HAC-X patients. This group incorpo-
rated both patients who failed to meet the pathway’s
inclusion criteria who were transferred inappropriately
and patients who had chest pain with an abnormal ECG
but who were subsequently shown to have a negative
troponin measured 12 h after onset of symptoms. In
patients in whom myocardial infarction was suspected at
presentation, the rapid access to coronary angiography
and early demonstration of unobstructed coronary arter-
ies allowed other cardiac diagnoses to be considered. In
patients with a ‘non-coronary’ cardiac diagnosis, such as
myocarditis, the early access to advanced non-invasive
cardiac imaging at the cardiac centre undoubtedly
streamlined their hospital admission, allowing earlier
Figure 2 Bee swarm boxplot demonstrating the time the
emergency departments admission to coronary angiography
for patients with suspected acute coronary syndromes treated
before (Pre-HAC-X, Heart Attack Centre-Extension) and after
(Post-HAC-X) the initiation of the HAC-X clinical pathway.
Each point represents the time taken to undergo coronary
angiography for an individual patient.
Figure 3 The proportion of patients with suspected acute
coronary syndromes undergoing coronary angiography within
recommended 96 h of hospital admission before (Pre-HAC-X,
Heart Attack Centre-Extension) and after (Post-HAC-X) the
initiation of the HAC-X clinical pathway.
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diagnosis and treatment. The small proportion of
patients transferred with a non-cardiac diagnosis could
be treated then discharged rapidly and safely from the
cardiac centre, meaning that they were little burden on
our resources. Although we strived to manage the vast
majority of post-HAC-X patients exclusively at the
cardiac centre, a small proportion of patients with a
non-cardiac diagnosis were ‘repatriated’ to their district
hospital for specialised further management of their
condition.
It should be noted that direct comparison of
pre-HAC-X and post-HAC-X patients is problematic.
Inclusion to the study occurred once patients were trans-
ferred to the cardiac centre (for coronary angiography
in pre-HAC-X patients, and with suspected NSTE-ACS
for assessment and/or coronary angiography in
post-HAC-X patients) rather than at the district hospital.
As a result, a proportion of patients in the post-HAC-X
group, after review at the cardiac centre were thought to
have a non-coronary diagnosis, and did not undergo cor-
onary angiography. Undoubtedly, before the initiation of
the HAC-X pathway a number of patients were admitted
to the district hospital with suspected NSTE-ACS, but
this diagnosis was discounted after local cardiology
review. These patients initially suspected to have
NSTE-ACS, but later proven to have a non-coronary
diagnosis, while still in their district hospital were not
included in the pre-HAC-X cohort. Furthermore, there
are important differences in the baseline demographics
between the patient cohorts (table 1). Post-HAC-X
patients were younger, more likely to be current smokers
and more commonly had a history of hypercholesterol-
aemia, previous PCI and peripheral vascular disease.
There are several potential explanations for these differ-
ences in cohort demographics. First, the presence of
coronary risk factors or a history of previous PCI in
patients presenting to the ED with chest pain is likely to
stimulate early cardiac investigations. Inclusion criteria
for the HAC-X pathway were diagnosis of NSTE-ACS
while in the ED. Older patients with a paucity of coron-
ary risk factors and no cardiac history may have had a
delayed NSTE-ACS diagnosis meaning they could not be
transferred directly from the ED via the HAC-X pathway.
Second, patients with major medical comorbidities that
precluded early angiography were speciﬁcally excluded
from the HAC-X pathway. This is likely to introduce a
degree of selection bias within the cohorts. The
post-HAC-X cohort was generally younger and ﬁtter, and
this may have facilitated early discharge and a reduced
length of hospital stay. Importantly, patients with
NSTE-ACS with exclusions to the HAC-X pathway who
were clinically unstable were always transferred to the
interventional centre for further management, although
these patients are not represented in this study.
Limitations of study
A number of limitations of this study are worthy of note;
ﬁrst, this was an observational study designed to evaluate
the feasibility of a novel change in practice to reduce
waiting times for coronary angiography in patients with
NSTE-ACS. We did not collect clinical outcome data on
the entire cohort and so can only speculate as to
whether the initiation of this pathway provided clinical
beneﬁt to the patients presenting with NSTE-ACS.
Second point of care troponin testing was not available
in the ED until the initiation of the HAC-X pathway.
Thus pre-HAC-X, patients will have undergone labora-
tory troponin testing whereas post-HAC-X patients
underwent point of care troponin testing. These tropo-
nin assays, have differing sensitivity and speciﬁcities; for
example point of care assays are designed to be highly
sensitive, but may lack speciﬁcity compared with stand-
ard laboratory assays.11 This may predispose to the inclu-
sion of patients with presumed NSTE-ACS who
subsequently receive a non-cardiac diagnosis. Despite
this limitation inappropriate transfers via the HAC-X
pathway were infrequent. The HAC-X clinical pathway
was designed to identify patients with NSTE-ACS while
they remained in the ED. There are patients with sus-
pected NSTE-ACS with an initially normal ECG and
negative point of care troponin that develop ECG abnor-
malities or a positive troponin assay later in their hos-
pital admission. Thus some patients with NSTE-ACS
continued to be admitted to the DGH even after the ini-
tiation of the HAC-X pathway. Patients with NSTE-ACS
admitted to the DGH, in the post-HAC-X era were
managed in a similar fashion to pre-HAC-X patients,
with medical stabilisation and transfer to the interven-
tional centre once a bed became available. We have not
collected data on this small group of patients. We do not
know how the inclusion of these patients may have
affected our results. Third, two of the six DGH’s served
by the London Chest Hospital have on-site cardiac cath-
eterisation laboratories offering diagnostic coronary
angiography but not PCI. Potentially, a small number of
patients with suspected NSTE-ACS could have under-
gone diagnostic coronary angiography locally and then
either been discharged if no coronary revascularisation
was indicated or referred directly for coronary surgery.
As patient data for this study were collected only after
referral for coronary angiography and/or PCI at the
interventional centre these patients with NSTE-ACS
bypassed study enrolment and thus are not represented
within the study cohort. However, we believe that the
standardised transfer criteria for patients with NSTE-ACS
central to the HAC-X pathway would make DGH admis-
sion and local angiography for patients with NSTE-ACS
less common in the post-HAC-X period. Finally, the
cardiac centre increased bed capacity, providing a dedi-
cated six bed ward for patients admitted via the HAC-X
pathway. The small increase in the total bed capacity of
the hospital coupled with more efﬁcient utilisation of
inpatient beds allowed the HAC-X pathway to function.
Potentially, these changes may confound our results, as
they may inﬂuence time to coronary angiography and
length of hospital stay.
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THE FUTURE
Delivery of coronary angiography within 96 h for
patients with NSTE-ACS admitted to hospitals without
facilities for invasive cardiac investigations is challenging.
The HAC-X pathway is effective in identifying patients
with NSTE-ACS for transfer directly to the regional
cardiac centre avoiding unnecessary delays in treatment.
Use of this model, modiﬁed according to local circum-
stances, could be applied nationally to streamline the
management of patients with NSTE-ACS. The invest-
ment required for ‘HAC-X’ beds would be more than
offset by the resulting savings in hospital bed days.
CONCLUSION
The introduction of this novel care pathway was asso-
ciated with signiﬁcant reductions in time to angiography
and in total hospital bed occupancy for patients with
NSTE-ACS. We have demonstrated its feasibility in
routine clinical practice so this model could be used
more widely to streamline the management of patients
with NSTE-ACS.
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